Lexicon SVP awarded RSUs and stock options

Lexicon Pharmaceuticals executive Brian T. Crum, SVP, General Counsel and Secretary, reported equity awards on February 12, 2026.

Rhea-AI Filing Summary

Lexicon Pharmaceuticals executive Brian T. Crum, SVP, General Counsel and Secretary, reported equity awards on February 12, 2026. He was granted 299,710 restricted stock units, each representing the right to receive one share of common stock as they vest.

The restricted stock units vest in three equal installments on February 28 of each of the three years following the grant year. Crum was also granted a stock option for 449,560 shares at an exercise price of $1.37 per share, vesting 25% after one year and the remainder in equal monthly installments over the next three years.

Insider Trade Summary

Grant/Award: 749,270 shares

Grant/Award 2 txns

Insider Crum Brian T

Role SVP, General Counsel & Secr.

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	299,710	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	449,560	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 299,710 contracts (Direct); Stock Option (Right to Buy) — 449,560 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock.
2. F2. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
3. F3. Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Lexicon Pharmaceuticals (LXRX) report for Brian T. Crum?

Lexicon Pharmaceuticals reported that Brian T. Crum received equity awards, including restricted stock units and stock options, on February 12, 2026. These awards were granted as part of his compensation and are subject to multi-year vesting schedules tied to continued service with the company.

How many restricted stock units were granted to the Lexicon (LXRX) executive?

Brian T. Crum was granted 299,710 restricted stock units. Each unit represents a contingent right to receive one share of Lexicon common stock, vesting in three equal installments on February 28 in each of the three years following the year in which the grant was made.

What are the terms of the stock options granted to Brian T. Crum at Lexicon (LXRX)?

Crum received a stock option covering 449,560 shares of Lexicon common stock at an exercise price of $1.37 per share. The option vests 25% on the first anniversary of the grant date and then 1/48th of the shares monthly for each month of continued service.

When do Brian T. Crum’s Lexicon (LXRX) restricted stock units vest?

The restricted stock units granted to Brian T. Crum vest over three years. One-third of the 299,710 units vests on February 28 of each of the three years following the year of grant, contingent on his continued service with Lexicon Pharmaceuticals during that period.

Is the Lexicon (LXRX) Form 4 transaction a stock purchase by Brian T. Crum?

No, the Form 4 reports equity awards granted to Brian T. Crum rather than open-market purchases. He acquired restricted stock units and a stock option as compensation, both with specified vesting schedules and an option exercise price of $1.37 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crum Brian T

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD.

11TH FLOOR

(Street)

THE WOODLANDS TX 77381

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel & Secr.

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/12/2026		A		299,710		(2)	(2)	Common Stock	299,710	$0	299,710	D
Stock Option (Right to Buy)	$1.37	02/12/2026		A		449,560		(3)	02/12/2036	Common Stock	449,560	$0	449,560	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

3. Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

	/s/ Brian T. Crum	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.